<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1491">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559009</url>
  </required_header>
  <id_info>
    <org_study_id>AH-NSI-COVID19-ALS</org_study_id>
    <nct_id>NCT04559009</nct_id>
  </id_info>
  <brief_title>COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry</brief_title>
  <official_title>COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative
      disease characterized by progressive weakness involving limb, bulbar, and respiratory
      muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed
      with amyotrophic lateral sclerosis (ALS). This is especially important as respiratory
      compromise is common in ALS patients and can complicate the clinical course as COVID-19 could
      lead to respiratory failure and need for intubation. We intend that this registry will guide
      our understanding of how COVID-19 affects patients with ALS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this registry is to assess the incidence and prevalence of COVID-19 in ALS
      patients, the effect of COVID-19 on ALS disease trajectory, and the impact, if any, of
      edaravone, riluzole and other concomitant medication used in ALS like Albuterol and
      dextromethorphan/quinidine (Nuedexta) on these parameters. COVID-19 incidence and prevalence
      in the ALS population will be assessed through outcomes reporting ranging from recovered
      infections to patient death reported in a patient facing registry.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>COVID-19 incidence and prevalence in the ALS population</measure>
    <time_frame>Data will be collected through study completion, an average of 3 years</time_frame>
    <description>Assessed through outcomes reporting ranging from recovered infections to patient death reported in a patient facing registry.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Our study population consists of qualifying cases of patients with ALS who have had a
        laboratory confirmed COVID-19 infection.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ALS and

          -  A confirmed COVID-19 infection determined by:

               1. positive SARS-CoV-2 viral RNA PCR test and/or

               2. positive serology antibody testing for SARS-CoV-2

        Exclusion Criteria:

          -  No ALS diagnosis

          -  No confirmed COVID-19 infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urvi Desai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurologist/ MDA Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erica Gowan</last_name>
    <phone>704-446-1982</phone>
    <email>erica.gowan@atriumhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Allison Newell-Sturdivant, MSN, BSN</last_name>
    <phone>704-355-5285</phone>
    <email>allison.newell-sturdivant@atriumhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neurosciences Institute, Neurology - Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2020</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Urvi Desai</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

